ArticleScientific reports2026
YBX1/PPIB axis promotes post-maturation arteriovenous fistula stenosis via enhancing endothelial to mesenchymal transition.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arteriovenous fistulas (AVFs) exhibit a high incidence of stenosis after maturation, which is a major cause of access failure in hemodialysis patients. However, its cellular heterogeneity and molecular mechanisms are not well clarified. For patients with post-maturation AVF stenosis (AVFS), we applied single-cell RNA sequencing on AVFS and matched non-stenotic vessels, followed by differential expression and pathway analyses to identify candidate cell types, genes and potential functional changes. Upstream transcription factors of the candidate genes were predicted using AnimalTFDB. The predicted molecular pathway was validated in vitro using HUVECs. Dual-luciferase assays tested transcription factor-gene interactions; qRT-PCR and Western blotting measured expression levels; immunofluorescence staining detected α-SMA; and wound healing assays assessed cell migration. Eight vascular cell types were identified, with endothelial cells showing the greatest proportional increase in AVFS. Differential expression analysis highlighted PPIB as the candidate gene, and enrichment analyses implicated endothelial-to-mesenchymal transition (EndMT). PPIB could promotes EndMT, as indicated by decreased VE-cadherin/CD31, increased α-SMA, and enhanced migration. Upstream transcription factor prediction identified YBX1 as a direct transcriptional regulator of PPIB, and dual-luciferase assays confirmed their interaction. YBX1 overexpression elevated PPIB levels and accelerated EndMT, whereas PPIB knockdown reversed these effects. This study reveals a novel YBX1–PPIB regulatory axis driving EndMT in endothelial cells, thereby contributing to post-maturation AVFS pathogenesis. These findings provide mechanistic insights and suggest potential therapeutic targets for preventing post-maturation AVFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.